Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish ...

Zoetis (NYSE:ZTS) added ~7% in the premarket on Tuesday after the animal health company exceeded Street forecasts with its Q2 ...

Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

Zoetis Inc. closed 25.61% short of its 52-week high of $200.33, which the company reached on September 19th.

Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.

Zoetis enjoys enviable financial flexibility, even as leverage ticked up in 2015 to finance the purchase of Pharmaq and Abbott's animal health business. With long-term debt at roughly $5.2 billion ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.